Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Leukemia, chronic lymphocytic (CLL)
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 138 for your search:
Start Over
Autologous Peripheral Blood Stem Cell Transplant in Treating Patients with Lymphoma
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT 2004-24, NCI-2010-01414, 0508M72589, 2005LS048, UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
Risk-Adapted Therapy in Treating Young Patients with Mature B-Cell Lymphoma or Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 0 to 21
Trial IDs: SJBC3, NCI-2011-01251, NCI-2010-00129, NCT01046825
Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: not specified
Trial IDs: 2448.00, NCI-2010-02035, NCT01231412
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Status: Enrolling by invitation
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR100955, NCI-2013-02262, 2012-004225-24, PCI-32765CAN3001, NCT01804686
Ibrutinib and Rituximab Compared with Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: E1912, NCI-2014-00118, ECOG-E1912, NCT02048813
A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: IPI-145-12, NCI-2014-02041, NCT02049515
A Study to Compare the Efficacy and Safety of Obinutuzumab + GDC-0199 Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: BO25323, NCI-2015-00926, 2014-001810-24, NCT02242942
Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: UTX-IB-301, NCI-2015-00855, NCT02301156
Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ACE-CL-006, NCI-2015-01966, NCT02477696
Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, Acalabrutinib (ACP-196) + Obinutuzumab, and Acalabrutinib in Subjects With Previously Untreated CLL
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ACE-CL-007, NCI-2015-02261, NCT02475681
Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Untreated and Previously Treated Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: UTX-TGR-304, NCI-2016-00375, NCT02612311
Alemtuzumab Before Donor Stem Cell Transplant in Treating Patients With Hematologic Diseases
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 70 and under
Trial IDs: HIMSUM, NCI-2012-00639, NCT00058825
Lenalidomide and AT-101 in Treating Patients with Relapsed B-Cell Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MC128A, NCI-2009-01569, NCT01021345, NCT01003769
Pyrimethamine in Treating Patients with Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 09-421, NCI-2010-01303, NCT01066663
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TED10893, NCI-2010-02332, U1111-1116-5472, NCT01084252
Vaccine Therapy and Lenalidomide in Treating Patients With B-Cell Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 75
Trial IDs: H-30087, NCI-2013-01015, RV-CLL-PI-0715, TAIL, NCT01604031
Allogeneic Stem Cell Transplant for Chronic Lymphocytic Leukemia (CLL)
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 2012-0249, NCI-2012-01248, NCT01629511
Inotuzumab Ozogamicin, Fludarabine Phosphate, Bendamustine Hydrochloride, and Rituximab before Donor Stem Cell Transplant in Treating Patients with Lymphoid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: 2012-0265, NCI-2012-02072, NCT01664910
Azacitidine in Treating Patients Undergoing Matched Unrelated Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 201303012, NCI-2012-03105, NCT01747499
Laboratory Treated T Cells in Treating Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2639.00, NCI-2013-00073, 2639, NCT01865617
AP1903 and Genetically Modified Donor T Cells after Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 2012-0501, NCI-2013-01666, RM00000684-RN00, NCT01875237
ALT-803 in Treating Patients with Relapsed Hematologic Malignancy after Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2012LS023, NCI-2013-02279, HM2013-12, NCT01885897
Pralatrexate and Romidepsin in Treating Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: AAAJ5656, NCI-2014-01986, NCT01947140
Phase 1/2A Dose Escalation Study in CLL, SLL or NHL
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-601, NCI-2014-00784, NCT01994382
Start Over